...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of intellectual property management >Obvious to try and non-obviousness post KSR: origins and implications
【24h】

Obvious to try and non-obviousness post KSR: origins and implications

机译：KSR之后可以尝试和不显而易见：起源和含义

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Non-obviousness is often considered 'the ultimate condition of patentability'. It tries to capture 'the technical accomplishment rather than economic implications'. Developments subsequent to Supreme Court's decision in Cuno engineering led to the introduction of non-obviousness as a criterion for patentability under 35 USC § 103 in 1952. In its efforts to bring uniformity, the Federal Circuit adopted the teaching suggestion and motivation test to define the scope of the prior art. In this paper, we proposed to illustrate how a seemingly obvious invention results in a conclusion of non-obviousness and leads to an industrially significant patent by examining the US patent application 11/574781 which deals with the 'process for producing Amlodipine enantiomer in high optical purity' for non-obviousness. We conclude with implications of the 'obvious to try' doctrine in the determination of non-obviousness in pharmaceutical inventions and the steps an applicant could take in establishing non-obviousness of the invention.
机译：非显而易见性通常被认为是“可专利性的最终条件”。它试图抓住“技术成就而不是经济意义”。最高法院在Cuno工程方面的判决之后的发展导致根据1952年《美国法典》第35篇第103条引入了非显而易见性作为可专利性的标准。​​在努力实现统一性的过程中，联邦巡回法院采用了教学建议和动机测试来定义现有技术的范围。在本文中，我们提议通过研究美国专利申请11/574781来说明看似显而易见的发明如何导致非显而易见性结论并导致一项具有重大工业意义的专利，该申请涉及“高光学氨氯地平对映体的制备方法”。纯度”表示不明显。我们以“显而易见的尝试”学说的含义作为结论来确定药物发明中的非显而易见性，以及申请人在确定发明中的非显而易见性时可以采取的步骤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号